

# REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 8103170542 DOC. DATE: 81/03/12 NOTARIZED: NO DOCKET #  
 FACIL: 50-275 Diablo Canyon Nuclear Power Plant, Unit 1, Pacific Gas & Electric Co. 05000275  
 50-323 Diablo Canyon Nuclear Power Plant, Unit 2, Pacific Gas & Electric Co. 05000323  
 AUTH. NAME: CRANE, P.A. AUTHOR AFFILIATION: Pacific Gas & Electric Co.  
 RECIP. NAME: MIRAGLIA, F.J. RECIPIENT AFFILIATION: Licensing Branch 3

SUBJECT: Notices of rept to be prepared by 810715 re adequacy of safety-related masonry walls. Rept will address identification, design review, Structural Engineering Branch design criteria, deficiencies & implementation schedule.

DISTRIBUTION CODE: B001S COPIES RECEIVED: LTR 1 ENCL 0 SIZE: 2  
 TITLE: PSAR/FSAR AMDTS and Related Correspondence

NOTES: 1 cy: J Hanchett (Region V) 05000275  
 1 cy: J Hanchett (Region V) 05000323

	RECIPIENT ID CODE/NAME	COPIES LTR ENCL	RECIPIENT ID CODE/NAME	COPIES LTR ENCL
ACTION:	A/D LICENSNG	1	MIRAGLIA, F.	1
	LEE, J.	1	BUCKLEY, B. 04	1
INTERNAL:	ACCID EVAL BR26	1	AUX SYS BR 07	1
	CHEM ENG BR 08	1	CONT SYS BR 09	1
	CORE PERF BR 10	1	EFF TR SYS BR12	1
	EMERG PREP 22	1	EQUIP QUAL BR13	3
	GEOSCIENCES 14	1	HUM FACT ENG BR	1
	HYD/GEOL BR 15	2	I&C SYS BR 16	1
	I&E 06	3	LIC GUID BR	1
	LIC QUAL BR	1	MATL ENG BR 17	1
	MECH ENG BR 18	1	MPA	1
	NRC RDR 18 1987 02	1	OELD	1
	OP LIC BR	1	POWER SYS BR 19	1
	PROC/TST REV 20	1	QA BR 21	1
	RAD ASSESS BR22	1	REAC SYS BR 23	1
	REG FILES 01	1	SIT ANAL BR 24	1
	STRUCT ENG BR25	1	SYS INTERAC BR	1
EXTERNAL:	ACRS 27	16	LPDR 03	1
	NSIC 05	1		

MAR 18 1981

TOTAL NUMBER OF COPIES REQUIRED: LTR 57 ENCL 51

1. *Pharmaceutical industry* – The pharmaceutical industry is a major contributor to the U.S. economy, with sales of over \$200 billion in 2000. The industry is characterized by high research and development costs, long time to market, and high barriers to entry. The industry is also heavily regulated by the FDA.

2. *Healthcare providers* – Healthcare providers, including hospitals, physicians, and nursing homes, are the primary users of pharmaceuticals. They are responsible for the distribution and administration of drugs to patients.

3. *Insurance companies* – Insurance companies, including Medicare and Medicaid, are responsible for paying for the costs of pharmaceuticals. They play a significant role in determining the prices of drugs.

4. *Pharmaceutical distributors* – Pharmaceutical distributors, including wholesalers and retailers, are responsible for the distribution of drugs from manufacturers to healthcare providers.

5. *Pharmaceutical consumers* – Pharmaceutical consumers, including patients and their families, are the ultimate users of drugs. They are responsible for paying for the costs of their medications.

The pharmaceutical supply chain is a complex system that involves the interaction of these five groups. The flow of drugs from manufacturers to patients is a multi-step process that involves the distribution of drugs through various channels.

The pharmaceutical supply chain is also characterized by high costs and low margins. The high costs of research and development, combined with the high costs of distribution and administration, result in high prices for patients.

The pharmaceutical supply chain is a critical component of the healthcare system. It is responsible for the distribution of drugs to patients, and it plays a significant role in determining the costs of healthcare.

The pharmaceutical supply chain is a complex system that involves the interaction of five groups: pharmaceutical manufacturers, healthcare providers, insurance companies, pharmaceutical distributors, and pharmaceutical consumers. The flow of drugs from manufacturers to patients is a multi-step process that involves the distribution of drugs through various channels. The pharmaceutical supply chain is also characterized by high costs and low margins. The high costs of research and development, combined with the high costs of distribution and administration, result in high prices for patients. The pharmaceutical supply chain is a critical component of the healthcare system. It is responsible for the distribution of drugs to patients, and it plays a significant role in determining the costs of healthcare.

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The *Agrobacterium* strains were incubated in the presence of the *Agrobacterium* suspension for 24 h. The transformation efficiency was determined by the number of transformants per 10<sup>6</sup> cells. The data are the mean  $\pm$  SD of three independent experiments.

1. The first group of people who are likely to be affected by the proposed project are the local residents who live in the vicinity of the project site. These residents may be affected by the project in a number of ways, including increased traffic, noise, and air pollution. The project may also affect the local economy by creating jobs and increasing the demand for goods and services. The project may also affect the local environment by increasing the demand for water and electricity, and by increasing the risk of flooding and other natural disasters.

[illegible][illegible]

*Sipinski*

# PACIFIC GAS AND ELECTRIC COMPANY

PG&E



P. O. BOX 7442 • 77 BEALE STREET, 31ST FLOOR, SAN FRANCISCO, CALIFORNIA 94106  
TELEPHONE (415) 781-4211

TELECOPIER (415) 543-7813

MALCOLM H. FURBUSH  
VICE PRESIDENT AND GENERAL COUNSEL

ROBERT OHLBACH  
ASSOCIATE GENERAL COUNSEL

CHARLES T. VAN DEUSEN  
PHILIP A. CRANE, JR.

HENRY J. LAPLANTE  
JOHN B. GIBSON

ARTHUR L. HILLMAN, JR.  
CHARLES W. THISSELL

DANIEL E. GIBSON  
ASSISTANT GENERAL COUNSEL

March 12, 1981

GILBERT L. HARRICK  
GLENN WEST, JR.  
JOSEPH I. KELLY  
HOWARD V. GOLUS  
JAMES G. LOGSDON  
ROBERT L. BORDON  
PETER W. HANSCHEN  
RICHARD F. LOCKE  
DAVID L. LUDVIGSON  
WILLIAM H. EDWARDS  
F. RONALD LAUFMEIER  
ROBERT R. RICKETT  
DAVID J. WILLIAMSON  
BRUCE R. WORTHINGTON

SENIOR COUNSEL

EDWARD J. MCGANNEY  
DAN GRAYSON LUSBOCK  
JACK F. FALLIN, JR.  
BERNARD J. DELLASANTA  
JOSHUA BAR-LEV  
JOSEPH S. ENGLERT, JR.  
ROBERT L. HARRIS  
DOUGLAS A. GOLESBY  
J. PETER BAUMGARTNER  
JOHN N. FRYE  
J. MICHAEL REIDENBACH  
IVON E. SAMSON  
SHIRLEY A. WOOD


DAVID W. ANDERSON  
DIANA BERGHAUSEN  
LEIGH S. CASSIDY  
AUDREY DAINES  
DONALD D. ERICKSON  
PATRICK D. GOLDEN  
PAULA Y. HAYNES  
RICHARD G. JONES  
HARRY W. LONG, JR.  
JOHN R. LOW  
ROBERT B. MCLENNAN  
RICHARD M. MOSS  
SHIRLEY A. SANDERSON  
JACK W. SHUCK  
KENNETH YAND

LATHAN T. ANNAND  
STEVEN P. BURKE  
PAMELA CHAPPELLE  
DARY P. ENCHINAS  
DAVID G. GILBERT  
STEVEN F. GREENWALD  
JUAN M. JAYD  
NEREK E. LIPSON  
JESSICA LORING  
A. KIRK MCKENZIE  
RICHARD L. MEISS  
ROGER J. PETERS  
JO ANN SHAFFER  
LOUIS E. VINCENT

ATTORNEYS

Mr. Frank J. Miraglia, Jr., Chief  
Licensing Branch No. 3  
Division of Licensing  
Office of Nuclear Reactor Regulation  
U. S. Nuclear Regulatory Commission  
Washington, DC 20555

Re: Docket No. 50-275  
Docket No. 50-323  
Diablo Canyon Units 1 and 2



Dear Mr. Miraglia:

Regarding the concrete block masonry walls at the Diablo Canyon Nuclear Plant, PG&E intends to prepare a report for the NRC which will identify, analyze and evaluate the adequacy of all safety-related masonry walls in the plant. As reported in the PG&E response to the NRC dated April 21, 1980, the walls have been identified, re-evaluated, and modified to assure compliance with PG&E criteria established prior to Bulletin 80-11.

This report will address the following specific items:

1. Identification: All walls will be listed in a table which will provide a physical description, the location of the walls in the plant, and any safety-related equipment adjacent to or supported on the walls. Floor plans locating the walls will be attached.
2. Design Review:
  - A. The calculations for the governing walls will be evaluated according to the requirements of the IE Bulletin 80-11.
  - B. The QA/QC procedures and practices followed during design and construction will be evaluated against the requirements of 10 CFR 50, Appendix B.

*Boo 1/10*

8103170542



March 12, 1981

3. Deviations from Structural Engineering Branch (SEB) Design Criteria:

The report will discuss deviations, if any, from the SEB interim criteria for the design of masonry walls and justify such deviations. A discussion of the impact of such deviations will be included.

4. Deficiencies:

- A. Seismically Inadequate Walls: All walls that do not meet design criteria and whose failure could damage safety-related equipment will be identified. A method of wall reinforcing will be described.
- B. Seismically Adequate Walls: Walls which are seismically adequate but do not meet the QA and QC requirements of Appendix B to 10 CFR 50 will be documented as follows:
  - 1. Their proximity to safety-related equipment will be identified.
  - 2. Typical design calculations of the walls will be included in the report.
  - 3. Test data for establishing material properties will be described.
  - 4. Documentation or a test program demonstrating that walls were constructed in conformance with design requirements will be described or, as an alternative, a justification that assumed construction deficiencies are acceptable will be provided.

5. Implementation Schedule:

- A. The report will include a schedule indicating the completion dates for any required modifications to the walls.
- B. Prior to full power operation any modifications required by the re-evaluation pursuant to Bulletin 80-11 will be completed.
- C. Before the end of the first refueling all differences between the staff interim criteria and PGandE criteria will be resolved and any additional fixes implemented.

The report as described above will be transmitted to the NRC for review and approval by July 15, 1981.

Very truly yours,

*Philip A. Grone*

